Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) have received an average rating of “Hold” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and five have issued a buy recommendation on the company. […]
Cantor Fitzgerald restated their overweight rating on shares of PTC Therapeutics (NASDAQ:PTCT – Get Rating) in a research note published on Friday morning, Zacks.com reports. A number of other research analysts have also weighed in on PTCT. Barclays cut their target price on shares of PTC Therapeutics from $40.00 to $39.00 and set an equal […]
PTC Therapeutics (NASDAQ:PTCT – Get Rating)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report issued on Friday, Zacks.com reports. Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of PTC Therapeutics from $70.00 to $76.00 and […]
Cantor Fitzgerald reissued their overweight rating on shares of PTC Therapeutics (NASDAQ:PTCT – Get Rating) in a report released on Friday, Zacks.com reports. Several other research firms also recently commented on PTCT. Zacks Investment Research downgraded shares of PTC Therapeutics from a buy rating to a sell rating in a report on Wednesday, January 26th. […]
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) has earned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average […]